This will be a human laboratory study evaluating the influence of pentoxifylline treatment on the effects of cocaine. Supported by and included in the Helping to End Addiction Long-term® (HEAL) Initiative.

Start Date01 Nov 2025

Sponsor / Collaborator

University of Kentucky

[+1]

NL-OMON56992

/ RecruitingNot Applicable

Unraveling cocaine metabolism in patients with cocaine use disorder for the purpose of potentially improving bioanalytical tests for cocaine use - Unraveling cocaine metabolism in patients with CUD

Start Date12 Nov 2024

Sponsor / Collaborator-

NCT06443255

/ CompletedPhase 3IIT

Comparison of Cocaine, Lidocaine/xylometazoline and Saline for Intranasal Analgesia - a Blinded Triple Crossover Study

When performed by trained personnel nasotracheal intubation is a safe and effective technique for attaining a secure airway in preparation for surgery of the head and neck. The procedure can be deemed necessary due to the nature of the surgical procedure or considerations in regard to the patient's comorbidities. For a certain group of patients with expected difficult airways, the procedure is done whilst they are awake and aided by fiberoptics.
For these awake patients, extra precautions must be taken to ensure the procedure is conducted with minimal pain and discomfort. The pain and discomfort arises from the mechanical manipulation of the nasal mucosa and can be alleviated in part by means of topical analgesia as well as through decongestion, providing more space within the nasal cavity. For these purposes, several drugs in varying combinations and dosages are used, but no single drug choice is universally recommended.
Cocaine is one of these appropriate drugs. It is a magistral formula used especially due to its unique combination of both vasoconstrictive and analgesic properties. Concerns have though been raised regarding cocaine's potential toxicity and alternative medications are continuously sought after.
A combination of lidocaine and xylometazoline can also be used for preparation of the nose prior to awake nasal fiberoptic intubation. Lidocaine contributes with its analgesic effect whilst xylometazoline functions as the vasoconstrictor.
The investigators wish to compare the analgesic effects of cocaine and lidocaine/phenylephrine to each other and saline when subjectively scored on a visual analogue scale of 0-100 mm immediately after simulated awake nasal intubation on healthy volunteers.

Start Date01 Jul 2024

Sponsor / Collaborator

Rigshospitalet

100 Clinical Results associated with Cocaine Hydrochloride

100 Translational Medicine associated with Cocaine Hydrochloride

100 Patents (Medical) associated with Cocaine Hydrochloride

42,754

Literatures (Medical) associated with Cocaine Hydrochloride

01 Feb 2026·BIOELECTROCHEMISTRY

Innovative magnetic bead-based electrochemical platform for rapid and sensitive cocaine detection in biological fluids

Article

Author: Cetinkaya, Ahmet ; Zouari, Mohamed ; Ozkan, Sibel A

Detecting psychoactive substances in biological samples presents significant challenges in clinical diagnostics, forensic analysis, and public health monitoring. This study introduces a highly sensitive electrochemical biosensing platform for the detection of cocaine, addressing the critical need for rapid, field-deployable testing methods. By integrating functionalized magnetic beads (MBs) with screen-printed carbon electrodes (SPCEs), we developed a competitive immunoassay system that leverages the superior molecular recognition capabilities of antibodies while maintaining operational simplicity. The biosensor operates via a competitive binding mechanism, in which cocaine present in the sample competes with cocaine-bovine serum albumin (BSA) conjugates immobilized on MBs for binding sites on horseradish peroxidase-labeled anti-cocaine antibodies (HRP-DAb). Electrochemical detection is achieved through amperometric measurement of enzyme activity using a redox system consisting of hydrogen peroxide/hydroquinone (H₂O₂/HQ). The optimized biosensor demonstrates excellent analytical performance with a linear response range from 0.3 to 300 ng mL^-1 and a detection limit of 0.1 ng mL^-1. Notably, the biosensor maintains its performance when analyzing cocaine in complex biological matrices, including human saliva and urine, successfully quantifying concentrations with minimal matrix interference. The platform offers significant advantages, including single-use disposable electrodes, rapid analysis time (< 30 min), minimal sample preparation requirements, and the potential for miniaturization into portable devices. These characteristics combined with high selectivity, a simple fabrication process, and cost-effectiveness, position this biosensor as a promising tool for point-of-care testing and field applications in clinical, forensic, and roadside testing scenarios.

01 Jan 2026·BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Is tau pathology a relevant factor in neuronal damage induced by alcohol and other drugs?

Review

Author: Quintanilla, Rodrigo A ; Ancía, Andrés ; Olesen, Margrethe A

Unrestricted alcohol consumption and other substances like methamphetamine (ecstasy), opioids, cannabis, and cocaine have generated serious health concerns in the world population. The abusive use of these substances produces neuropathological alterations that could lead to cognitive decline and neurodegeneration. Pathological damage generated by these drugs resembles neurodegenerative changes observed in neurological disorders (NDs), including Alzheimer's disease (AD), Parkinson's disease (PD), and others. One of the relevant elements distinguished in these diseases is the aggregation of intraneuronal proteins and deregulation of the neuronal cytoskeleton. In this context, the toxic modification of tau protein, a microtubule-associated protein (MAP), has raised new interest in drug and alcohol abuse research. Tau can undergo different pathological changes in which its anomalous phosphorylation and truncation state are relevant for NDs. These modifications produce a detachment from microtubule structures, affecting axonal transport and synaptic plasticity. Current studies suggest that alcohol and drug abuse may affect the mechanisms behind tau phosphorylation, inducing dysregulation of kinase/phosphatase activities and toxic tau accumulation. These alterations could be a key element that contributes to cognitive decline and neurodegeneration caused by substance abuse. Therefore, it is pivotal to understand how alcohol and other drugs contribute to neuronal damage by inducing tau pathology. This knowledge could generate new strategies and biomedical targets to reduce addictive consumption, neurodegeneration, and cognitive decline produced by substance abuse.

31 Dec 2025·HIV Research & Clinical Practice

A peculiar case of persistent CPK elevation in a person diagnosed with acute HIV: what is behind?

Article

Author: Cattelan, Annamaria ; Pegoraro, Elena ; Nalesso, Federico ; Dal Bello, Luca ; Marinello, Serena ; Calandrino, Lucrezia ; Mazzitelli, Maria ; Ferrari, Anna

INTRODUCTION:

The coexistence of common and rare conditions in a single person may represent a diagnostic challenge. We herein report the case of a young gentleman diagnosed with an acute HIV infection who had a history of myalgias and exercise intolerance and experienced elevated creatinine and phosphokinase enzyme levels.

CLINICAL PRESENTATION:

A 24-year-old gentleman was diagnosed with an acute HIV in May 2023 (HIV-RNA > 10.000.000 copies/ml, CD4+ count 417 cell/L) and started same-day combinarion antiretroviral therapy, cART, with darunavir/cobicistat/tenofovir alafenamide/emtricitabine+dolutegravir), switching to dolutegravir/lamivudine once undetectable, 6 weeks after. After 5 months, he was hospitalized with fever, headache, and acute renal failure (creatinine 500 umol/L). Later, CPK peaked at >22,000 mg/dl. He denied chemsex/drug use and had recently started exercising on a regular basis. HIV-RNA was undetectable, cerebrospinal fluid (CSF) examination was unremarkable. cART was temporarily stopped with the normalization of labs. After 20 days, cART was restarted, as well as physical activity, with relapse of the symptoms requiring rehospitalization. Workups for autoimmune and infectious causes were negative. Suspecting drug-related myositis (data on myopathies under integrase inhibitors have been reported), muscle MRI, muscle biopsy, genetic analyses, hair analysis were performed. He tested positive for cocaine and amphetamines. Muscle biopsy showed type 1 fiber atrophy while muscle magnetic resonance imaging was unremarkable. In January 2025, genetic testing came back confirming type VII glycogenosis.

DISCUSSION:

This case highlights the diagnostic complexity of rare metabolic disorders, especially when coexisting with acute HIV, continuous medication use and drug exposure. It allows us to highlight the importance of considering rare metabolic disorders as differential diagnoses, as they can mimic systemic illnesses or drug-related effects.

245

News (Medical) associated with Cocaine Hydrochloride

23 Oct 2025

·www.globenewswire.com

Intelligent Bio Solutions Secures Major UK Contract with Multinational Industrial Service Provider

Multinational company employs approximately 3,000 staff within the UK and Ireland and more than 30,000 staff worldwide Large new customer account highlights accelerating adoption of the Company's rapid, non-invasive drug testing technology across high-volume, safety-critical sectors NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has secured a major new contract with one of the United Kingdom's largest industrial service providers. The multinational company, a global leader operating across the energy, defence, nuclear, and industrial sectors, employs more than 30,000 people worldwide and services complex, safety-critical projects across Europe, the Middle East, and Asia-Pacific. Within the UK and Ireland, the company employs approximately 3,000 staff across multiple sites. The new customer account represents one of INBS's most significant UK commercial deployments to date. The adoption of INBS’s drug testing technology forms part of the customer’s group-wide change initiative to modernize workforce safety and compliance. The customer's existing testing process, based on urine collection and third-party testing, was identified as slow and operationally disruptive. By transitioning to INBS's Intelligent Fingerprinting Drug Screening System, the customer expects to achieve faster, cleaner, and more efficient testing that reduces downtime, increases productivity, and delivers rapid results at point of testing. Strong internal support reinforced the transition decision, with stakeholders highlighting the benefits of a less invasive method, improved employee experience, and shorter detection windows. Feedback from customer representatives indicated the move to INBS’s technology was viewed not as a question of if, but when and how, it could be implemented across the organization’s workforce. “Securing this account highlights the expanding market confidence in our technology and its growing role in transforming drug testing across some of the world's largest industrial operators,” said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. "Each new enterprise adoption validates our value proposition, strengthens our commercial trajectory, and expands recurring consumables revenue potential." The addition of another global enterprise customer reflects INBS’s continued momentum following multiple deployments across the transportation, construction, and mining sectors. These successes are driving increased adoption of the Company’s razor–razor-blade business model, underpinning long-term recurring cartridge sales and sustained revenue growth. INBS’s drug testing technology is used by over 480 accounts in 24 countries, with 18 distribution partners expanding its global reach. The Company continues to expand its international footprint while progressing on the regulatory pathway in seeking FDA 510(k) clearance to enter the U.S. workplace testing market beyond the Forensic Use Only category. About Intelligent Bio Solutions Inc.   Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners.   For more information, visit https://ibs.inc/ Forward-Looking Statements  Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions’ public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.  Company Contact  Intelligent Bio Solutions Inc.   info@ibs.inc LinkedIn | Twitter   Investor & Media Contact  Valter Pinto, Managing Director   KCSA Strategic Communications   PH: (212) 896-1254   INBS@kcsa.com 

26 Sep 2025

·www.globenewswire.com

Intelligent Bio Solutions Advances Preparations and Provides Updated Timeline for Anticipated FDA 510(k) Submission and Clearance

The Company is initiating clinical studies to further validate Intelligent Fingerprinting Drug Screening System INBS anticipates FDA 510(k) clearance in the second half of 2026 NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today is providing an update on the timeline for anticipated FDA 510(k) clearance for the use of its Intelligent Fingerprinting Drug Screening System for the opiate codeine. Following recent feedback from the U.S. Food and Drug Administration (FDA), INBS has established a pathway to gather additional supporting data to strengthen its new 510(k) submission to the FDA. The Company plans to commence clinical studies to further validate its Intelligent Fingerprinting Drug Screening System before calendar year-end. These studies are scheduled to conclude in the first half of the 2026 calendar year. INBS anticipates FDA 510(k) clearance in the second half of the 2026 calendar year. “We have a clear and achievable timeline for resubmitting our 510(k) application. The additional clinical data we are generating will supplement existing data and strengthen our package,” said Peter Passaris, Vice President of Product Development at Intelligent Bio Solutions. “We are committed to bringing our innovative technology to the U.S. market, while continuing to focus on the growth of the overall business.” INBS’s drug testing technology has been adopted by over 450 accounts in 24 countries, with 18 distribution partners expanding its global reach. The Company continues to advance its commercial operations outside the U.S., with growing adoption across industries, including construction, transportation, logistics, and mining, while simultaneously working toward FDA clearance for U.S. entry beyond the Forensic Use Only market. About Intelligent Bio Solutions Inc. Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners. For more information, visit https://ibs.inc/ Forward-Looking Statements Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions’ public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. Company Contact Intelligent Bio Solutions Inc.info@ibs.incLinkedIn | Twitter Investor & Media Contact Valter Pinto, Managing DirectorKCSA Strategic CommunicationsPH: (212) 896-1254INBS@kcsa.com

IND

17 Sep 2025

·www.globenewswire.com

Intelligent Bio Solutions Provides Update on FDA 510(k) Clearance Process for Intelligent Fingerprinting Drug Screening System

NEW YORK, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today provided an update on its FDA 510(k) clearance process for its Intelligent Fingerprinting Drug Screening System. In December 2024, INBS submitted its 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for review and clearance of its Intelligent Fingerprinting Drug Screening System. As expected, the FDA reviewed and responded with questions by issuing an Additional Information (AI) request in February 2025. This AI request consisted of over 70 items to be addressed by the Company. With the support of specialized FDA consultants and expert third-party partners, INBS responded to the FDA’s questions and submitted additional information in August 2025. The FDA appeared to be satisfied with the majority of responses to the items and has responded with a request for new additional information that requires the Company to resubmit a new 510(k) notification. As a first-of-its-kind device with no comparable cleared or approved sweat-based product currently on the market, the Company’s Intelligent Fingerprinting Drug Screening System requires extensive supporting information to validate its performance. The practical feedback received from the FDA is not uncommon for breakthrough technologies. INBS is in the process of evaluating the FDA’s questions and is currently in consultation with its specialized FDA consultants. The Company expects to have an investor update in the next ten days outlining an updated timeline for FDA clearance. “The FDA’s feedback provides constructive clarity on the additional information it requires to advance our application,” said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. “We are confident in the capabilities of our technology, and we remain fully committed to bringing our innovative solution to the U.S. market. We will work to respond to the FDA’s additional questions to support validation of our device, in order to resubmit our 510(k) Notification as soon as possible. The progress we have made so far in terms of additional data collected to substantiate the strength of our product throughout this process places us in a strong position as we work toward clearance. Importantly, our international business continues to grow, enabling us to maintain commercial progress globally while pursuing U.S. clearance outside of the Forensic Use Only market.” The Company continues to advance its commercial activities outside the U.S., developing new partnerships and driving sales growth while pursuing further international market penetration. About Intelligent Bio Solutions Inc. Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners. For more information, visit https://ibs.inc/ Forward-Looking Statements Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions’ public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. Company Contact Intelligent Bio Solutions Inc. info@ibs.inc LinkedIn | Twitter Investor & Media Contact Valter Pinto, Managing Director KCSA Strategic Communications PH: (212) 896-1254 INBS@kcsa.com

100 Deals associated with Cocaine Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D02182	Cocaine Hydrochloride	S01HA01 S02DA02 N01BC01	DB00907

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Anesthesia	United States	Noden Pharma DAC	14 Dec 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cocaine-Related Disorders	Phase 2	United States	Biotie Therapies Oy	01 Jun 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05809453 (CTgov)	Phase 1/2	Hyperthermia	27	Cocaine+lidocaine (Hot-Humid: Cocaine)	vmynkpuetr(lcslyyhnvr) = yggbidolte apkqfmvlks (yayatbhaqy, 0.32) View more	-	14 Jul 2025
				Lidocaine (Hot-Humid: Lidocaine)	vmynkpuetr(lcslyyhnvr) = btoflyvqkd apkqfmvlks (yayatbhaqy, 0.33) View more
NCT02537873 (CTgov)	Phase 1	Cocaine-Related Disorders	29	Cocaine+Lorcaserin (Arm 1: Lorcaserin and Cocaine IV)	cmhbzpdavb(bgsovkatxp) = txeloavvxp rphgcmucbn (spzugeuzhc, 7.98) View more	-	12 May 2020
				Cocaine+Placebo comparator (Arm 2: Placebo Comparator and Cocaine IV)	cmhbzpdavb(bgsovkatxp) = gcjtqtgmyt rphgcmucbn (spzugeuzhc, 6.94) View more
NCT01906346 (CTgov)	Early Phase 1	Cocaine-Related Disorders	9	Placebo+Cocaine (Low Value Alternative Reinforcer)	opsfdkywms(dmzuefzkbo) = cfxgvdvmnl vmuzmkjoqu (mcoccgousf, 1.39) View more	-	17 May 2019
				Placebo+Cocaine (Medium Value Reinforcer)	opsfdkywms(dmzuefzkbo) = yapigacwww vmuzmkjoqu (mcoccgousf, 0.53) View more
NCT02383043 (CTgov)	Early Phase 1	Cocaine-Related Disorders	18	Cocaine+Sustained Release d-Amphetamine	dxbsvapktt(cvggrnjzuf) = giixzcaydx palticfffj (lyxudtuaho, 0.35) View more	-	11 Apr 2019
ACR2017	Not Applicable	Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis ANCA antibodies \| inflammatory markers \| haematology and biochemistry profiles	14	Cocaine-induced vasculitis	ffczsinyjj(plzjycoedv) = nnrxfhokkb zjfysjoerb (azsbxirctr ) View more	Negative	06 Nov 2017
				Cocaine (Idiopathic ANCA vasculitis)	ffczsinyjj(plzjycoedv) = yhenoljuco zjfysjoerb (azsbxirctr )
NCT00373880 (CTgov)	Phase 2	Cocaine-Related Disorders	26	Placebo+Cocaine (Placebo + 0mg Cocaine)	dbnyhgzqas(wydogffepp) = ypqmctcbiw oqrtkogatz (cdihgchdku, 0) View more	-	11 Sep 2017
				Placebo+Cocaine (Placebo + 12mg Cocaine)	dbnyhgzqas(wydogffepp) = jlrrvdjasm oqrtkogatz (cdihgchdku, 0.5) View more
NCT01706952 (CTgov)	Phase 4	Chronic sinusitis	45	Cocaine+Adrenaline (Cocaine)	oqnqcjjzvb(jafvygitbx) = keheruidiu iydarfmlok (qrhcoukkdu, anlgagwfkq - qodkkmhbwl) View more	-	03 May 2017
				Cocaine+Adrenaline (Adrenaline)	oqnqcjjzvb(jafvygitbx) = zsznqskeux iydarfmlok (qrhcoukkdu, itrfkwvtnn - xwpegrkfds) View more
NCT02233647 (CTgov)	Early Phase 1	Cocaine-Related Disorders	11	Phendimetrazine	yublsnlmed(mxoqkrnqsd) = nttgqavxlu qrxctucpvh (ywycrjhmof, 2.54) View more	-	15 Sep 2016
SurvUDI study (IAS2002)	Not Applicable	-	-	Cocaine injection	yzsryaqxsi(oyjvnljtrm) = xzurpprzdh ziuhgzehlb (epypgmvlxx, 3.6 - 5.0) View more	-	01 Jan 2002

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis